Cargando…
Targeted Assessment of the EGFR Status as Reflex Testing in Treatment-Naive Non-Squamous Cell Lung Carcinoma Patients: A Single Laboratory Experience (LPCE, Nice, France)
Background: Assessment of actionable EGFR mutations is mandatory for treatment-naïve advanced or metastatic non-squamous lung carcinoma (NSLC), but the results need to be obtained in less than 10 working days. For rapid EGFR testing, an EGFR-specific polymerase chain reaction (PCR) assay is an alter...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225982/ https://www.ncbi.nlm.nih.gov/pubmed/32294880 http://dx.doi.org/10.3390/cancers12040955 |
_version_ | 1783534180331683840 |
---|---|
author | Lassalle, Sandra Hofman, Véronique Heeke, Simon Benzaquen, Jonathan Long, Elodie Poudenx, Michel Lantéri, Elisabeth Boutros, Jacques Tanga, Virginie Zahaf, Katia Lalvée, Salomé Lespinet, Virginie Bordone, Olivier Félix, Jean-Marc Bonnetaud, Christelle Marquette, Charles Ilie, Marius Hofman, Paul |
author_facet | Lassalle, Sandra Hofman, Véronique Heeke, Simon Benzaquen, Jonathan Long, Elodie Poudenx, Michel Lantéri, Elisabeth Boutros, Jacques Tanga, Virginie Zahaf, Katia Lalvée, Salomé Lespinet, Virginie Bordone, Olivier Félix, Jean-Marc Bonnetaud, Christelle Marquette, Charles Ilie, Marius Hofman, Paul |
author_sort | Lassalle, Sandra |
collection | PubMed |
description | Background: Assessment of actionable EGFR mutations is mandatory for treatment-naïve advanced or metastatic non-squamous lung carcinoma (NSLC), but the results need to be obtained in less than 10 working days. For rapid EGFR testing, an EGFR-specific polymerase chain reaction (PCR) assay is an alternative and simple approach compared to next generation sequencing (NGS). Here, we describe how a rapid EGFR-specific PCR assay can be implemented in a single laboratory center (LPCE, Nice, France) as reflex testing in treatment-naïve NSLC. Methods: A total of 901 biopsies from NSLC with more than 10% of tumor cells were prospectively and consecutively evaluated for EGFR mutation status between November 2017 and December 2019 using the Idylla system (Biocartis NV, Mechelen, Belgium). NGS was performed for nonsmokers with NSLC wild type for EGFR, ALK, ROS1, and BRAF and with less than 50% PD-L1 positive cells using the Hotspot panel (Thermo Fisher Scientific, Waltham, MA, USA). Results: Results were obtained from 889/901 (97%) biopsies with detection of EGFR mutations in 114/889 (13%) cases using the Idylla system. Among the 562 EGFR wild type tumors identified with Idylla, NGS detected one actionable and one nonactionable EGFR mutation. Conclusions: Rapid and targeted assessment of EGFR mutations in treatment-naïve NSLC can be implemented in routine clinical practice. However, it is mandatory to integrate this approach into a molecular algorithm that allows evaluation of potentially actionable genomic alterations other than EGFR mutations. |
format | Online Article Text |
id | pubmed-7225982 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72259822020-05-18 Targeted Assessment of the EGFR Status as Reflex Testing in Treatment-Naive Non-Squamous Cell Lung Carcinoma Patients: A Single Laboratory Experience (LPCE, Nice, France) Lassalle, Sandra Hofman, Véronique Heeke, Simon Benzaquen, Jonathan Long, Elodie Poudenx, Michel Lantéri, Elisabeth Boutros, Jacques Tanga, Virginie Zahaf, Katia Lalvée, Salomé Lespinet, Virginie Bordone, Olivier Félix, Jean-Marc Bonnetaud, Christelle Marquette, Charles Ilie, Marius Hofman, Paul Cancers (Basel) Article Background: Assessment of actionable EGFR mutations is mandatory for treatment-naïve advanced or metastatic non-squamous lung carcinoma (NSLC), but the results need to be obtained in less than 10 working days. For rapid EGFR testing, an EGFR-specific polymerase chain reaction (PCR) assay is an alternative and simple approach compared to next generation sequencing (NGS). Here, we describe how a rapid EGFR-specific PCR assay can be implemented in a single laboratory center (LPCE, Nice, France) as reflex testing in treatment-naïve NSLC. Methods: A total of 901 biopsies from NSLC with more than 10% of tumor cells were prospectively and consecutively evaluated for EGFR mutation status between November 2017 and December 2019 using the Idylla system (Biocartis NV, Mechelen, Belgium). NGS was performed for nonsmokers with NSLC wild type for EGFR, ALK, ROS1, and BRAF and with less than 50% PD-L1 positive cells using the Hotspot panel (Thermo Fisher Scientific, Waltham, MA, USA). Results: Results were obtained from 889/901 (97%) biopsies with detection of EGFR mutations in 114/889 (13%) cases using the Idylla system. Among the 562 EGFR wild type tumors identified with Idylla, NGS detected one actionable and one nonactionable EGFR mutation. Conclusions: Rapid and targeted assessment of EGFR mutations in treatment-naïve NSLC can be implemented in routine clinical practice. However, it is mandatory to integrate this approach into a molecular algorithm that allows evaluation of potentially actionable genomic alterations other than EGFR mutations. MDPI 2020-04-13 /pmc/articles/PMC7225982/ /pubmed/32294880 http://dx.doi.org/10.3390/cancers12040955 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lassalle, Sandra Hofman, Véronique Heeke, Simon Benzaquen, Jonathan Long, Elodie Poudenx, Michel Lantéri, Elisabeth Boutros, Jacques Tanga, Virginie Zahaf, Katia Lalvée, Salomé Lespinet, Virginie Bordone, Olivier Félix, Jean-Marc Bonnetaud, Christelle Marquette, Charles Ilie, Marius Hofman, Paul Targeted Assessment of the EGFR Status as Reflex Testing in Treatment-Naive Non-Squamous Cell Lung Carcinoma Patients: A Single Laboratory Experience (LPCE, Nice, France) |
title | Targeted Assessment of the EGFR Status as Reflex Testing in Treatment-Naive Non-Squamous Cell Lung Carcinoma Patients: A Single Laboratory Experience (LPCE, Nice, France) |
title_full | Targeted Assessment of the EGFR Status as Reflex Testing in Treatment-Naive Non-Squamous Cell Lung Carcinoma Patients: A Single Laboratory Experience (LPCE, Nice, France) |
title_fullStr | Targeted Assessment of the EGFR Status as Reflex Testing in Treatment-Naive Non-Squamous Cell Lung Carcinoma Patients: A Single Laboratory Experience (LPCE, Nice, France) |
title_full_unstemmed | Targeted Assessment of the EGFR Status as Reflex Testing in Treatment-Naive Non-Squamous Cell Lung Carcinoma Patients: A Single Laboratory Experience (LPCE, Nice, France) |
title_short | Targeted Assessment of the EGFR Status as Reflex Testing in Treatment-Naive Non-Squamous Cell Lung Carcinoma Patients: A Single Laboratory Experience (LPCE, Nice, France) |
title_sort | targeted assessment of the egfr status as reflex testing in treatment-naive non-squamous cell lung carcinoma patients: a single laboratory experience (lpce, nice, france) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225982/ https://www.ncbi.nlm.nih.gov/pubmed/32294880 http://dx.doi.org/10.3390/cancers12040955 |
work_keys_str_mv | AT lassallesandra targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance AT hofmanveronique targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance AT heekesimon targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance AT benzaquenjonathan targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance AT longelodie targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance AT poudenxmichel targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance AT lanterielisabeth targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance AT boutrosjacques targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance AT tangavirginie targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance AT zahafkatia targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance AT lalveesalome targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance AT lespinetvirginie targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance AT bordoneolivier targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance AT felixjeanmarc targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance AT bonnetaudchristelle targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance AT marquettecharles targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance AT iliemarius targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance AT hofmanpaul targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance |